Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05239182
Title 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Kansas Medical Center
Indications

pancreatic cancer

Therapies

9-ING-41 + Gemcitabine + Nab-paclitaxel + Retifanlimab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.